{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:27:42Z","timestamp":1789921662044,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Neurofibromatosis type 2-related schwannomatosis (NF2-SWN) is a rare genetic tumor syndrome causing progressive neurological morbidity. This systematic review evaluates current evidence on the effectiveness, safety, and patient-reported outcomes of these treatments, primarily in vestibular schwannomas.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020 guidelines. Comprehensive searches of PubMed, Cochrane Library, and Google Scholar were conducted up to November 2024 using Medical Subject Headings (MeSH) and a building-block approach. Eligible studies included patients with NF2-SWN treated with targeted systemic therapies, including vascular endothelial growth factor (VEGF) inhibitors, mammalian target of rapamycin inhibitors, tyrosine kinase inhibitors (TKIs), or immunotherapies. Data extraction captured study design, population, interventions, and outcomes across four domains: radiologic response, hearing response, adverse events, and quality of life (QoL).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Twelve studies (6 clinical trials, 2 systematic reviews, and 4 case reports) comprising 426 patients were included. Bevacizumab was the most extensively studied agent, demonstrating durable tumor stabilization, hearing preservation, and sustained QoL with manageable long-term toxicity. Mammalian target of rapamycin inhibitors (everolimus, vistusertib) and TKIs (brigatinib, anlotinib) primarily achieved cytostatic disease control, while an early phase VEGFR peptide vaccine showed partial radiologic responses and improved subjective well-being. Across all studies, grade \u22653 toxicities were uncommon, and no treatment-related deaths occurred.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Targeted systemic therapy offers a disease-modifying, function-preserving alternative to surgery or radiotherapy in NF2-SWN. Although current evidence supports safety and efficacy, larger multicenter randomized trials with standardized outcome measures are required to refine dosing strategies and confirm long-term benefit.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/nop\/npag017","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:25:45Z","timestamp":1771849545000},"page":"649-660","source":"Crossref","is-referenced-by-count":1,"title":["The effectiveness of targeted therapy in the treatment of patients with neurofibromatosis type 2-related schwannomatosis and vestibular schwannomas: A systematic review"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6278-1728","authenticated-orcid":false,"given":"Hala","family":"Rahman","sequence":"first","affiliation":[{"name":"Manchester University NHS Foundation Trust Plastic and Reconstructive surgery, , Manchester,","place":["United Kingdom (H.R.)"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithum","family":"Senaratne","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ruhuna , Galle, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Ajal","family":"Loueian","sequence":"additional","affiliation":[{"name":"American University of Integrative Sciences Department of Medicine, , Saint Michael, Barbados (M.A.L.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Kausheic","family":"Madhusuthanan","sequence":"additional","affiliation":[{"name":"Apollo Hospitals , Chennai,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Afzal","sequence":"additional","affiliation":[{"name":"Primary and Secondary Healthcare , Punjab,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Turuzhbaeva","sequence":"additional","affiliation":[{"name":"Samara State Medical University, General Medicine, Samara, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Kashmer D","family":"Yu","sequence":"additional","affiliation":[{"name":"Internal Medicine, California Institute of Behavioral Neurosciences & Psychology , Fairfield, California,","place":["United States (A.K.D.Y.)"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026071401512644300_npag017-B1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.otc.2023.02.013","article-title":"Targeted therapies in the treatment of vestibular schwannomas: current state and new horizons","volume":"56","author":"Welling","year":"2023","journal-title":"Otolaryngol Clin North Am"},{"key":"2026071401512644300_npag017-B2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yao.2024.01.002","article-title":"Updates on revised diagnostic criteria and targeted therapies for neurofibromatosis","volume":"4","author":"Santiago-Cruz","year":"2024","journal-title":"Adv Oncol"},{"key":"2026071401512644300_npag017-B3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12935-023-02940-8","article-title":"The genetic landscape and possible therapeutics of neurofibromatosis type 2","volume":"23","author":"Ghalavand","year":"2023","journal-title":"Cancer Cell Int"},{"key":"2026071401512644300_npag017-B4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41388-024-02958-w","article-title":"Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis","volume":"43","author":"Nagel","year":"2024","journal-title":"Oncogene"},{"key":"2026071401512644300_npag017-B5","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3390\/cancers16111961","article-title":"Integrating ataxia evaluation into tumor-induced hearing loss model to comprehensively study NF2-related schwannomatosis","volume":"16","author":"Lu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026071401512644300_npag017-B6","doi-asserted-by":"publisher","first-page":"941854","DOI":"10.3389\/fphar.2022.941854","article-title":"Qu-Du-San-Jie decoction induces growth inhibition and vascular normalization in NF2-associated vestibular schwannoma","volume":"13","author":"Lin","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026071401512644300_npag017-B7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1093\/neuonc\/noad037","article-title":"Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma","volume":"25","author":"Bhattacharyya","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026071401512644300_npag017-B8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00280-020-04229-3","article-title":"A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies","volume":"87","author":"Collier","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026071401512644300_npag017-B9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40487-024-00279-2","article-title":"Gene therapy for neurofibromatosis type 2-related schwannomatosis: recent progress, challenges, and future directions","volume":"12","author":"Yuan","year":"2024","journal-title":"Oncol Ther"},{"key":"2026071401512644300_npag017-B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026071401512644300_npag017-B11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1471-1842.2008.00825.x","article-title":"Unpacking your literature search toolbox: on search styles and tactics","volume":"25","author":"Booth","year":"2008","journal-title":"Health Info Libr J"},{"key":"2026071401512644300_npag017-B12","doi-asserted-by":"publisher","first-page":"e2165","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi","year":"2024","journal-title":"Health Sci Rep"},{"key":"2026071401512644300_npag017-B13","volume-title":"Checklist for Quasi-Experimental Studies (Non-Randomized Experimental Studies)","author":"Joanna Briggs Institute","year":"2017"},{"key":"2026071401512644300_npag017-B14","volume-title":"The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2011"},{"key":"2026071401512644300_npag017-B15","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"2026071401512644300_npag017-B16","volume-title":"Checklist for Case Reports","author":"Joanna Briggs Institute","year":"2017"},{"key":"2026071401512644300_npag017-B17","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026071401512644300_npag017-B18","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/neuonc\/noad066","article-title":"Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma","volume":"25","author":"Plotkin","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026071401512644300_npag017-B19","doi-asserted-by":"publisher","first-page":"103148","DOI":"10.1016\/j.amjoto.2021.103148","article-title":"Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: a systematic review and meta-analysis","volume":"42","author":"Shi","year":"2021","journal-title":"Am J Otolaryngol"},{"key":"2026071401512644300_npag017-B20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/CAD.0000000000000953","article-title":"Long-term therapy with bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature","volume":"31","author":"Nigro","year":"2020","journal-title":"Anticancer Drugs"},{"key":"2026071401512644300_npag017-B21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5414\/NP301464","article-title":"Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the NF2: c. 784C> T p.(Arg262) variant","volume":"41","author":"Basenach","year":"2022","journal-title":"Clin Neuropathol"},{"key":"2026071401512644300_npag017-B22","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00381-022-05531-6","article-title":"Multiple craniospinal tumors in a pediatric patient with neurofibromatosis type 2: a case report","volume":"38","author":"Kim","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"2026071401512644300_npag017-B23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11060-024-04596-4","article-title":"Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma","volume":"167","author":"Nghiemphu","year":"2024","journal-title":"J Neurooncol"},{"key":"2026071401512644300_npag017-B24","doi-asserted-by":"publisher","first-page":"vdad041","DOI":"10.1093\/noajnl\/vdad041","article-title":"Prospective phase II trial of the dual mTORC1\/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2","volume":"5","author":"Jordan","year":"2023","journal-title":"Neurooncol Adv"},{"key":"2026071401512644300_npag017-B25","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","article-title":"Brigatinib in NF2-related schwannomatosis with progressive tumors","volume":"390","author":"Plotkin","year":"2024","journal-title":"N Engl J Med"},{"key":"2026071401512644300_npag017-B26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/CAD.0000000000001502","article-title":"Treatment of neurofibromatosis type II with anlotinib: a case report and literature review","volume":"34","author":"Zhao","year":"2023","journal-title":"Anticancer Drugs"},{"key":"2026071401512644300_npag017-B27","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.23.02376","article-title":"Phase I\/II study of a vascular endothelial growth factor receptor vaccine in patients with NF2-related schwannomatosis","volume":"42","author":"Tamura","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026071401512644300_npag017-B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jocn.2021.01.010","article-title":"Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: systematic review and case","volume":"86","author":"Snyder","year":"2021","journal-title":"J Clin Neurosci"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npag017\/67115426\/npag017.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/4\/649\/67115426\/npag017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/4\/649\/67115426\/npag017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:51:36Z","timestamp":1784008296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/13\/4\/649\/8497912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npag017","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,2,25]]}}}